Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Innovent Biologics (1801N) Stock Price & Analysis

1801N Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
MXN 333.70B
Enterprise Value
MXN 122.92B
Total Cash (Recent Filing)
MXN 20.00B
Total Debt (Recent Filing)
MXN 2.32B
Price to Earnings (P/E)
95.4
Beta
N/A
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
3.11
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profit Inflection

The 2025 increase in revenue alongside a return to profitability indicates stronger commercial execution and product adoption. If sustained, this inflection can expand internal funding capacity for pipeline development, commercialization, and other investments over the next several quarters.

Strong Gross Margin

A rising gross margin demonstrates strong underlying economics in the commercial product portfolio and improves the amount of revenue available to support research, selling activity, and operating expenses. This provides a durable foundation for scaling if pricing and product mix remain favorable.

Conservative Balance Sheet

Low leverage and a larger equity base give Innovent financial flexibility to fund clinical programs, manufacturing capacity, and commercialization without relying as heavily on additional borrowing. The stronger capital structure also improves resilience if profitability or cash generation becomes more variable.

Bears Say

Unproven Profitability Durability

The 2025 profit is a meaningful improvement, but the preceding multi-year record of losses shows that sustainable earnings have not yet been established. Continued execution is required to prove that the recent improvement reflects a durable operating model rather than a temporary inflection.

Uneven Cash Flow History

Although 2025 cash generation was exceptionally strong, the earlier pattern of negative and inconsistent cash flow raises uncertainty about repeatability. A durable business model will need to demonstrate that operating cash can remain positive while Innovent continues funding development and commercialization activities.

Modest Net Profitability

The return to positive earnings has not yet translated into a high level of profitability relative to revenue or capital employed. Modest net margins and low recent returns leave less room to absorb higher development or commercial costs and make sustained execution important to long-term value creation.

Innovent Biologics News

1801N FAQ

What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is Mex$333.70B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 148 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported Mex$1.96 earnings per share for the quarter, beating the consensus estimate of Mex$1.316 by Mex$0.644.
Is Innovent Biologics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 3.11.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,746,918,300 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of Mex$1.96 in its last earnings report, beating expectations of Mex$1.316. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in MX:1801N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology